J9037 — Injection, belantamab mafodotin-blmf, 0.5 mg
J9037 is a HCPCS Level II code for injection, belantamab mafodotin-blmf, 0.5 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on March 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J9037 on March 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9037
- Long descriptor
- Injection, belantamab mafodotin-blmf, 0.5 mg
- Short descriptor
- Inj belantamab mafodot blmf
- Added
- April 1, 2021
- Terminated
- March 31, 2025
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9037
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9037 is not quite right, the correct code is very often within a few positions of it.
- J9029Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
- J9030Bcg live intravesical instillation, 1 mg
- J9031Bcg (intravesical) per instillationterminated
- J9032Injection, belinostat, 10 mg
- J9033Injection, bendamustine hydrochloride, 1 mg
- J9034Injection, bendamustine hcl (bendeka), 1 mg
- J9035Injection, bevacizumab, 10 mg
- J9036Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
- J9038Injection, axatilimab-csfr, 0.1 mg
- J9039Injection, blinatumomab, 1 microgram
- J9040Injection, bleomycin sulfate, 15 units
- J9041Injection, bortezomib, 0.1 mg
- J9042Injection, brentuximab vedotin, 1 mg
- J9043Injection, cabazitaxel, 1 mg
- J9044Injection, bortezomib, not otherwise specified, 0.1 mgterminated
- J9045Injection, carboplatin, 50 mg
Questions about J9037
What is HCPCS code J9037?
J9037 is a HCPCS Level II code for injection, belantamab mafodotin-blmf, 0.5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9037?
The CMS HCPCS file marks J9037 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J9037 still valid?
No. J9037 was terminated on March 31, 2025 and should not be used on new claims.